The American Thyroid Association (ATA) has published updated guidelines for the management of patients with thyroid nodules and differentiated thyroid cancer. The guidelines, developed by a task force of experts in endocrinology, surgery, and nuclear medicine, aim to provide evidence-based recommendations for diagnosis, treatment, and long-term management. The guidelines address the evaluation and follow-up of thyroid nodules, including the role of fine needle aspiration biopsy, the management of benign and malignant nodules, and the appropriate use of thyroid hormone suppression therapy. For differentiated thyroid cancer, the guidelines cover initial management, including preoperative staging, surgical options, and the role of radioiodine ablation. They also address long-term management, including the use of serum thyroglobulin measurements, imaging techniques, and the management of patients with metastatic disease. The guidelines emphasize the importance of accurate staging, the use of appropriate imaging modalities, and the need for individualized treatment based on risk stratification. The task force also discusses the role of external beam radiation and chemotherapy in the management of thyroid cancer. The guidelines highlight the importance of minimizing the risk of recurrence and metastasis through appropriate surgical and therapeutic interventions. The task force also addresses the use of recombinant human thyrotropin in lieu of thyroid hormone withdrawal for remnant ablation and the role of low-iodine diets in preparing patients for radioiodine therapy. The guidelines emphasize the importance of follow-up and surveillance for thyroid cancer, including the use of radioiodine scans and serum thyroglobulin measurements. The guidelines also address the management of patients with thyroglobulin-positive disease and the role of chemotherapy in the treatment of thyroid cancer. The task force concludes that future research is needed to further refine the management of thyroid nodules and differentiated thyroid cancer.The American Thyroid Association (ATA) has published updated guidelines for the management of patients with thyroid nodules and differentiated thyroid cancer. The guidelines, developed by a task force of experts in endocrinology, surgery, and nuclear medicine, aim to provide evidence-based recommendations for diagnosis, treatment, and long-term management. The guidelines address the evaluation and follow-up of thyroid nodules, including the role of fine needle aspiration biopsy, the management of benign and malignant nodules, and the appropriate use of thyroid hormone suppression therapy. For differentiated thyroid cancer, the guidelines cover initial management, including preoperative staging, surgical options, and the role of radioiodine ablation. They also address long-term management, including the use of serum thyroglobulin measurements, imaging techniques, and the management of patients with metastatic disease. The guidelines emphasize the importance of accurate staging, the use of appropriate imaging modalities, and the need for individualized treatment based on risk stratification. The task force also discusses the role of external beam radiation and chemotherapy in the management of thyroid cancer. The guidelines highlight the importance of minimizing the risk of recurrence and metastasis through appropriate surgical and therapeutic interventions. The task force also addresses the use of recombinant human thyrotropin in lieu of thyroid hormone withdrawal for remnant ablation and the role of low-iodine diets in preparing patients for radioiodine therapy. The guidelines emphasize the importance of follow-up and surveillance for thyroid cancer, including the use of radioiodine scans and serum thyroglobulin measurements. The guidelines also address the management of patients with thyroglobulin-positive disease and the role of chemotherapy in the treatment of thyroid cancer. The task force concludes that future research is needed to further refine the management of thyroid nodules and differentiated thyroid cancer.